Gara Jalqabaatti › Melanoma › Massachusetts › Boston
Qorannoo klinikaalii Melanoma Boston, MA keessatti
Qorannoo 26 Melanoma f Boston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Namoota walitti qabaa jiraSadarkaa 1/2
- Tufts Medical Center, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Namoota walitti qabaa jiraSadarkaa 2
- Local Institution - 0124, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Namoota walitti qabaa jiraSadarkaa 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Namoota walitti qabaa jiraSadarkaa 2
- Massachusetts General Hospital Cancer Center, Boston
Project: Every Child for Younger Patients With Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Namoota walitti qabaa jiraSadarkaa 1/2
- Call for Information (Investigational Site 0026), Boston
Video Education With Result Dependent dIsclosure
Namoota walitti qabaa jira
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Namoota walitti qabaa jiraSadarkaa 3
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Namoota walitti qabaa jiraSadarkaa 2/3
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Namoota walitti qabaa jiraSadarkaa 2/3
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Namoota walitti qabaa jiraSadarkaa 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Namoota walitti qabaa jiraSadarkaa 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Dana Farber Cancer Institute, Boston
Qorannoo Melanoma magaalota biroo keessatti
- Houston, TXQorannoo 59
- New York City, NYQorannoo 38
- Los Angeles, CAQorannoo 34
- Nashville, TNQorannoo 33
- Pittsburgh, PAQorannoo 31
- Philadelphia, PAQorannoo 23
- San Francisco, CAQorannoo 22
- Columbus, OHQorannoo 21
- Durham, NCQorannoo 21
- Atlanta, GAQorannoo 21
- Salt Lake City, UTQorannoo 21
- St. Louis, MOQorannoo 21
Qorannoo biroo Boston keessatti
- Saree OljooQorannoo 112
- Kansara Qara'a Non-Small CellQorannoo 90
- Saree (Gosoota Hunda)Qorannoo 85
- Kansara MetastatikiiQorannoo 63
- Kansarii ColorectalQorannoo 63
- Dhibee QaraQorannoo 62
- Kansarii OvariiQorannoo 61
- Kansarii ProstateQorannoo 59
- DepreshiniiQorannoo 52
- Kansa EndometiriyaaliiQorannoo 50
- Cufama OnneeQorannoo 44
- Leukemia Myeloidii HamaaQorannoo 44
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.